Thyroid eye disease progresses late

Thyroid eye disease is supposed to follow a familiar arc. The eyes get inflamed, symptoms build for roughly 18 months, and then the disease settles into a quieter phase. But new data presented May 4 at the ARVO 2026 meeting in Denver argues that this picture is too neat. In a real-world cohort of 34,590 adults, nearly 30% showed progression during follow-up, and about one in three worsened within 5 years of diagnosis. (healio.com)oid eye disease, exactly? It is the autoimmune eye disorder most closely linked to Graves disease, though it can also show up in people who are euthyroid or hypothyroid. The immune attack targets tissues around the eye — especially orbital fat and extraocular muscles — which can cause bulging, lid retraction, double vision, dryness, pain, and in severe cases optic nerve compression that threatens vision. (ccjm.org) inflammatory phase, then a plateau, then a more stable inactive phase. That model still helps doctors think about timing, but it also carries an implicit promise — that after enough time passes, the disease is mostly done doing new damage. The new ARVO presentation challenges that assumption. (healio.com)mhankar and colleagues ran a retrospective cohort study using two huge US data sources — the IRIS Registry and Komodo Health claims data. They tracked natural-history patterns in 34,590 adults with TED, using a 12-month baseline period starting at the earliest sign of TED and at least 12 months of follow-up after that. (healio.com)ened. It is when it happened. The presentation said progression was not confined to the early disease window. Some patients worsened years after diagnosis, which is exactly the kind of pattern the standard “active then burned out” story tends to miss. (healio.com)m of TED progression over the study period. About one-third progressed within 5 years of diagnosis. And 3.4% developed new sight-threatening disease, including compressive optic neuropathy. That last number matters because optic neuropathy is the emergency version of TED — it needs urgent treatment to prevent permanent vision loss. (healio.com) ### Why does this matter for actual care? Because a lot of follow-up logic still depends on the calendar. If a patient is several years out from diagnosis, both patient and clinician may assume new symptoms are just chronic leftovers rather than fresh progression. These data suggest the safer instinct is different — new diplopia, exposure symptoms, lid changes, or orbital complaints may deserve a real re-evaluation even in “longstanding” TED. (([healio.com)### Does this overturn everything doctors already use? Not really. Clinical guidelines still sort TED by activity and severity, often using the Clinical Activity Score and EUGOGO severity framework. But one recent guideline comparison points out that the ATA-ETA consensus already treats disease progression itself as an activity marker. Turns out this new dataset fits that more dynamic view pretty well. (link.springer.com)t yet tell us which patients are most likely to worsen late. But the broader TED literature is clear that smoking remains the biggest modifiable risk factor, and sight-threatening disease still demands a high index of suspicion no matter where someone sits on the timeline. (ccjm.org) ### Bottom line? The simple version is this: thyroid eye disease may not be “one(link.springer.com)hange, the disease may be changing too. (healio.com)